Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
4.
PLoS One ; 11(12): e0169129, 2016.
Article in English | MEDLINE | ID: mdl-28030635

ABSTRACT

BACKGROUND: Glioblastomas are the most frequent type of malignant primary brain tumor with a median overall survival less than 15 months. Therapy resistance of glioblastomas has been attributed to the presence of tumor initiating stem-like cells (TSCs). TSC-related markers have therefore been suggested to have promising potentials as prognostic markers in gliomas. METHODOLOGY/PRINCIPAL FINDINGS: The aim of the present study was to investigate the expression and prognostic impact of the TSC-related marker Oct-4 in astrocytic brain tumors of increasing grade. In total 114 grade II, III and IV astrocytic brain tumors were immunohistochemically stained for Oct-4, and the fraction and intensity of Oct-4 positive cells were determined by morphometric analysis of full tumor sections. Oct-4 was expressed in all tumors, and the Oct-4 positive cell fraction increased with tumor grade (p = 0.045). There was no association between survival and Oct-4 positive cell fraction, neither when combining all tumor grades nor in analysis of individual grades. Oct-4 intensity was not associated with grade, but taking IDH1 status into account we found a tendency for high Oct-4 intensity to be associated with poor prognosis in anaplastic astrocytomas. Double immunofluorescence stainings showed co-localization in the perivascular niches of Oct-4 and two other TSC markers CD133 and nestin in glioblastomas. In some areas Oct-4 was expressed independently of CD133 and nestin. CONCLUSIONS: In conclusion, high Oct-4 fraction was associated with tumor malignancy, but seemed to be without independent prognostic influence in glioblastomas. Identification of a potential prognostic value in anaplastic astrocytomas requires additional studies using larger patient cohorts.


Subject(s)
Astrocytoma/pathology , Biomarkers, Tumor/metabolism , Brain Neoplasms/pathology , Glioblastoma/pathology , Octamer Transcription Factor-3/metabolism , Adolescent , Adult , Aged , Astrocytoma/metabolism , Astrocytoma/therapy , Brain Neoplasms/metabolism , Brain Neoplasms/therapy , Case-Control Studies , Child , Child, Preschool , Combined Modality Therapy , Female , Follow-Up Studies , Glioblastoma/metabolism , Glioblastoma/therapy , Humans , Immunoenzyme Techniques , Male , Middle Aged , Neoplasm Staging , Prognosis , Survival Rate , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...